Efficiency of PRGF-Endoret in Combination With a Bone Graft in Lateral Sinus Floor Elevation

Sponsor
Fundación Eduardo Anitua (Other)
Overall Status
Completed
CT.gov ID
NCT01771302
Collaborator
Biotechnology Institute IMASD (Industry)
12
1
2
14.9
0.8

Study Details

Study Description

Brief Summary

This randomized clinical study investigates the efficiency of plasma rich in growth factors (PRGF-Endoret) in combination with bone grafts in the healing of bone and soft tissues after the performance of lateral sinus floor elevation.

The hypothesis of this study is that the use of PRGF-Endoret will produce similar bone formation regardless the type of bone graft.

Condition or Disease Intervention/Treatment Phase
  • Device: Bio-Oss
  • Device: calcium phosphate ceramic
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
12 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Randomized Clinical Trial on the Efficiency of PRGF-Endoret in Combination With a Bone Graft in Lateral Sinus Floor Elevation
Study Start Date :
Jan 1, 2013
Actual Primary Completion Date :
Apr 1, 2014
Actual Study Completion Date :
Apr 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Bio-Oss

the xenograft is of bovine origin where the organic phase has been eliminated.

Device: Bio-Oss
It is a bone substitute of bovine origin

Experimental: calcium phosphate ceramic

is a calcium phosphate biomaterial

Device: calcium phosphate ceramic
It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature

Outcome Measures

Primary Outcome Measures

  1. Percentage of newly-formed bone [6 months after surgical intervention]

    The histomorphometrical analysis of the biopsies taken after 6 months of surgical intervention (time for dental implants insertion) will be performed to calculate the primary outcome

Secondary Outcome Measures

  1. Bone density [at baseline and after 6 months of intervention]

    This data will be measured on the cone-beam CT scanners obtained at baseline and after 6 months of healing

  2. Insertion torque [6 months after surgical intervention]

    At the time of implant insertion and initial insertion torque will be registered

  3. Percentage of residual graft [6 months after surgical intervention]

    The histological analysis will determine the percentage of residual graft after 6 months of surgery.

  4. Pain index [7 days, 15 days, 1 month, 2 months, 6 months and 12 months after surgical intervention]

    This will evaluate the intensity of pain the patient suffered due to the surgical intervention.

  5. Healing index [7 days, 15 days and 1 month after surgical intervention]

    This index will evaluate the soft tissue healing.

  6. Infection [7 days, 15 days, 1 month, 2 months, 6 months and 12 months after surgical intervention]

    Notify the infection of the graft material

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients over 18 years

  • Patients requiring implant prostheses oral rehabilitation.

  • Patients with insufficient residual height in posterior maxilla requiring a sinus lift procedure to insert the implants

Exclusion Criteria:
  • Not having complete the informed consent form.

  • Sinusitis.

  • Alcoholism.

  • Suffering severe haematological disorder or disease.

  • Be undergoing or having received radiotherapy, chemotherapy or immunosuppressive therapy, corticosteroids and / or anticoagulants, 30 days prior to the study inclusion.

  • In usual treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or other anti-inflammatory drugs.

  • Background of chronic hepatitis or liver cirrhosis.

  • Diabetes mellitus with poor metabolic control (glycosylated hemoglobin above 9%)

  • Patients undergoing dialysis.

  • Presence of malignant tumors, hemangiomas or angiomas in the extraction area.

  • History of ischemic heart disease in the last year.

  • Pregnancy or intention to become pregnant during the study follow-up period.

  • Metabolic bone disease

  • Patients taking bisphosphonates drugs both orally and intravenously.

  • In general, any inability to participate in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinica Eduardo Anitua Vitoria Spain

Sponsors and Collaborators

  • Fundación Eduardo Anitua
  • Biotechnology Institute IMASD

Investigators

  • Principal Investigator: Eduardo Anitua, MD, DDS, PhD, Clinica Eduardo Anitua

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fundación Eduardo Anitua
ClinicalTrials.gov Identifier:
NCT01771302
Other Study ID Numbers:
  • BTI-EC/12/Biomat
First Posted:
Jan 18, 2013
Last Update Posted:
Aug 23, 2021
Last Verified:
Jul 1, 2015
Keywords provided by Fundación Eduardo Anitua
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2021